The European landscape for gene therapies in orphan diseases: 6-year experience with the EMA Committee for Orphan Medicinal Products
Gloria M. Palomo(Agencia Española de Medicamentos y Productos Sanitarios), Segundo Mariz(European Medicines Agency), Dinah Duarte(National Laboratory for Civil Engineering), Armando Magrelli(European Medicines Agency), Darius Matusevičius(European Medicines Agency), Dinko Vitezić(University of Rijeka), Tomás Pose‐Boirazian(European Medicines Agency), Maria Elisabeth Kalland(European Medicines Agency), Kristina Larsson(European Medicines Agency), Frauke Naumann‐Winter(Federal Institute for Drugs and Medical Devices), Enrico Costa(Brigham and Women's Hospital), Eva Malikova(European Medicines Agency), Violeta Stoyanova‐Beninska(European Medicines Agency)
Cited by 15
Related Papers
Outrageous prices of orphan drugs: a call for collaboration
|The Lancet|2018|160
The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis
|Orphanet Journal of Rare Diseases|2022|51
Efficacy and acceptability of antidepressants on the continuum of depressive experiences in patients with cancer: Systematic review and meta-analysis
|Cancer Treatment Reviews|2015|45
Making hydroxyurea affordable for sickle cell disease in Tanzania is essential (<scp>HASTE</scp>): How to meet major health needs at a reasonable cost
|American Journal of Hematology|2020|31
Acute hemolysis by hydroxycloroquine was observed in G6PD-deficient patient with severe COVD-19 related lung injury
|European Journal of Internal Medicine|2020|22